A federal appeals court has upheld an asset freeze against Reven Holdings and three company principals. The October 14 ruling keeps strict financial limits on a biotechnology firm that regulators say raised at least $44 million from roughly 175 investors through misleading disclosures.
What happened in the Reven Holdings case
The Securities and Exchange Commission sued Reven Holdings, Peter Lange, Brian Denomme, and Michael Volk in December 2022. According to the complaint, the principals raised at least $44 million from approximately 175 investors to develop Rejuveinix, a cardiovascular drug known as RJX. Regulators allege that offering documents described a promising clinical program while misrepresenting how much money the executives paid themselves.
The United States Court of Appeals for the Tenth Circuit affirmed a preliminary injunction and asset freeze that a lower court entered earlier in the litigation. The panel concluded that the SEC had raised serious questions going to the merits of the alleged fraud. The company had asked to loosen the freeze so clinical work on RJX could resume.
The executive pay numbers at the center of the case
The heart of the dispute is a gap between what investors were told and what bank records showed. Private placement memoranda told investors the principals received $1.62 million in 2019, $1.98 million in 2020, and $2.16 million in 2021. Wells Fargo banking records reviewed by the SEC’s accounting expert told a different story.
| Year | Compensation disclosed to investors | Amount shown in bank records |
|---|---|---|
| 2019 | $1.62 million | $5.35 million |
| 2020 | $1.98 million | $3.36 million |
| 2021 | $2.16 million | $6.65 million |
The district court found a likely discrepancy between $4.89 million and $9.78 million across the three years. Investors who funded the RJX program were, in effect, underwriting executive pay they could not see. The SEC charged the defendants under the antifraud provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934.
Why the appeals court ruling matters
The Tenth Circuit’s decision keeps the freeze intact while the SEC case moves forward. That matters for two reasons. First, frozen assets remain available to compensate investors if the agency prevails at trial. Second, the ruling signals that appellate judges viewed the alleged misstatements as substantial enough to justify extraordinary relief.
The defendants have contested the SEC’s claims. Reven has said publicly that the enforcement action damaged its standing with existing and potential investors, and the principals argued that the freeze stalled a drug they consider promising. The appeals court was unpersuaded that those concerns outweighed investor protection.
Red flags investors should recognize
Private biotechnology placements carry risks that public market investors rarely face. Several patterns in this case deserve attention from anyone weighing a private offering.
- Compensation opacity. Investors received executive pay figures that bank records later contradicted by millions of dollars.
- Concentrated control. Three principals held the chief executive, operating, and compliance roles at the same time.
- Story-heavy pitching. The RJX drug narrative carried the raise, while verifiable financial detail lagged behind the claims.
- Hard-to-verify milestones. Ordinary investors had no independent way to confirm the clinical progress they were promised.
What affected investors can do now
Investors who bought Reven Holdings offerings can take concrete steps while the litigation proceeds. Gather every subscription agreement, private placement memorandum, and payment record. Request account statements from the escrow agent or firm that processed the investment. Preserve all correspondence with anyone who solicited the purchase.
Some investors may also hold claims through their own brokerage or advisory relationships. If a financial professional recommended the RJX placement, that recommendation is itself reviewable for suitability and disclosure failures. Recovery claims tied to private placements run on strict deadlines, and waiting rarely improves a position.
Haselkorn & Thibaut fights for investor recovery
Haselkorn & Thibaut is a securities law firm founded by former Wall Street defense attorneys who shifted their practice to represent investors. The firm has recovered over $520 million for clients in securities matters and maintains a 98 percent success rate in resolved nontraded REIT cases. Attorneys are AV Preeminent rated through Martindale-Hubbell, designated as Super Lawyers, and hold a 5.0-star client review average. The firm operates on a contingency basis — no recovery, no fee.
Contact Haselkorn & Thibaut today
Time matters in private placement recovery cases. The earlier you act, the stronger your position. The firm offers a free case evaluation to assess your losses, review your account history, and explain your options under arbitration or settlement.
- Main Phone: 1-888-885-7162
- website for a free consultation
Offices in Florida, New York, Arizona, Texas, and North Carolina. Former Wall Street defense attorneys with 95+ years of combined experience. No recovery, no fee.
